New Imaging System Reduces Reoperation Rates in Breast Cancer Surgery

The BrIMA trial, which tracked 148 patients across Belgium, Germany, and Italy, found that the AURA 10 system allows for immediate intraoperative margin assessment. In cases of invasive ductal carcinoma, surgical success rates climbed from 83.3% to 95.2% when the technology was utilized. Across all breast cancer subtypes, the success rate improved from 76.4% to 91.9%. Unlike traditional methods that rely on limited two-dimensional views or delayed pathology reports, the XEOS device delivers high-resolution, three-dimensional molecular imaging in approximately ten minutes without requiring the specimen to leave the operating room.

Vincent Keereman, CEO of XEOS, noted that the core advantage is the ability to gain actionable insight while the patient is still on the table, rather than discovering residual cancer days later. Dr. Menekse Göker, the study's primary author at Ghent University Hospital, emphasized that the system integrates into routine surgical workflows without disrupting the procedure. With no device-related adverse events reported during the three-year study, the technology offers a pathway to reducing the physical and emotional burden of reoperations while potentially lowering healthcare costs associated with secondary interventions.